• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一例伴有EGFR突变及周围PD-L1阳性肿瘤相关巨噬细胞的PD-L1阴性肺腺癌患者对纳武单抗的长期反应

A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages.

作者信息

Watanabe Hiromi, Ohashi Kadoaki, Nishii Kazuya, Seike Keisuke, Makimoto Go, Hotta Katsuyuki, Maeda Yoshinobu, Kiura Katsuyuki

机构信息

Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan.

Department of Respiratory Medicine, Okayama University Hospital, Japan.

出版信息

Intern Med. 2019 Oct 15;58(20):3033-3037. doi: 10.2169/internalmedicine.2875-19. Epub 2019 Jul 10.

DOI:10.2169/internalmedicine.2875-19
PMID:31292383
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6859382/
Abstract

Anti-programmed cell death 1 (PD-1) antibodies have poor efficacy in epidermal growth factor receptor (EGFR)-mutated lung cancer. We herein report a 72-year-old man with programmed cell death-ligand 1 (PD-L1)-negative lung adenocarcinoma harboring an EGFR mutation that responded to nivolumab for more than 2 years. A pathological examination revealed infiltration of CD8-positive lymphocytes and macrophages expressing CD68, CD206, and PD-L1 into the PD-L1-negative tumor; CD206 expression is a marker of immunosuppressive tumor-associated macrophages (TAMs). The presence of PD-L1-positive TAMs in the tumor environment might be a predictor of a positive response to anti-PD-1 antibodies.

摘要

抗程序性细胞死亡蛋白1（PD-1）抗体在表皮生长因子受体（EGFR）突变的肺癌中疗效不佳。我们在此报告一名72岁男性，患有携带EGFR突变的程序性细胞死亡配体1（PD-L1）阴性肺腺癌，对纳武单抗反应超过2年。病理检查显示，CD8阳性淋巴细胞和表达CD68、CD206和PD-L1的巨噬细胞浸润到PD-L1阴性肿瘤中；CD206表达是免疫抑制性肿瘤相关巨噬细胞（TAM）的标志物。肿瘤环境中存在PD-L1阳性TAM可能是对抗PD-1抗体产生阳性反应的一个预测指标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77ec/6859382/157c7ffbc84d/1349-7235-58-3033-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77ec/6859382/48f6ffe2be1a/1349-7235-58-3033-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77ec/6859382/d0c89bde5101/1349-7235-58-3033-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77ec/6859382/157c7ffbc84d/1349-7235-58-3033-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77ec/6859382/48f6ffe2be1a/1349-7235-58-3033-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77ec/6859382/d0c89bde5101/1349-7235-58-3033-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77ec/6859382/157c7ffbc84d/1349-7235-58-3033-g003.jpg

相似文献

1
A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages.一例伴有EGFR突变及周围PD-L1阳性肿瘤相关巨噬细胞的PD-L1阴性肺腺癌患者对纳武单抗的长期反应
Intern Med. 2019 Oct 15;58(20):3033-3037. doi: 10.2169/internalmedicine.2875-19. Epub 2019 Jul 10.
2
Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma.表皮生长因子受体（EGFR）突变对肺腺癌患者 PD-1 抑制剂临床疗效的影响。
J Cancer Res Clin Oncol. 2019 May;145(5):1341-1349. doi: 10.1007/s00432-019-02889-0. Epub 2019 Mar 21.
3
Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations.回顾性分析 EGFR 突变的 NSCLC 患者使用纳武利尤单抗的抗肿瘤作用及生物标志物。
PLoS One. 2019 Apr 12;14(4):e0215292. doi: 10.1371/journal.pone.0215292. eCollection 2019.
4
Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.程序性死亡配体1表达可预测表皮生长因子受体突变阳性肺腺癌患者队列中酪氨酸激酶抑制剂的反应及更好的预后。
Clin Lung Cancer. 2015 Sep;16(5):e25-35. doi: 10.1016/j.cllc.2015.02.002. Epub 2015 Feb 19.
5
Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma.纳武单抗对一名PD-L1阴性肺腺癌患者的颅内反应
Intern Med. 2018 Nov 1;57(21):3149-3152. doi: 10.2169/internalmedicine.9884-17. Epub 2018 Jun 6.
6
Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma.病例报告：程序性细胞死亡 1 配体 1 阳性和多个基因驱动的间变性淋巴瘤激酶酪氨酸激酶抑制剂耐药肺腺癌患者对纳武利尤单抗的完全应答。
Front Immunol. 2021 Nov 4;12:686057. doi: 10.3389/fimmu.2021.686057. eCollection 2021.
7
A Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Non-Small Cell Lung Carcinoma.在非鳞状非小细胞肺癌中，评估程序性细胞死亡配体 1 表达以预测纳武利尤单抗治疗患者反应时，单一活检样本中需要至少有 100 个肿瘤细胞。
J Thorac Oncol. 2019 Oct;14(10):1818-1827. doi: 10.1016/j.jtho.2019.06.019. Epub 2019 Jun 28.
8
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.表皮生长因子受体（EGFR）突变和间变性淋巴瘤激酶（ALK）重排与非小细胞肺癌中PD-1通路阻断的低反应率相关：一项回顾性分析
Clin Cancer Res. 2016 Sep 15;22(18):4585-93. doi: 10.1158/1078-0432.CCR-15-3101. Epub 2016 May 25.
9
Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression.肺腺癌的异质性成分赋予其独特的 EGFR 突变和 PD-L1 表达。
BMC Cancer. 2020 Feb 24;20(1):148. doi: 10.1186/s12885-020-6631-z.
10
Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.非小细胞肺癌突变中的免疫标志物分析和程序性死亡配体 1 表达。
J Thorac Oncol. 2018 Dec;13(12):1884-1896. doi: 10.1016/j.jtho.2018.09.012. Epub 2018 Sep 26.

引用本文的文献

1
Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1/PD-L1 blockade in the clinical spectrum of lung cancer.在肺癌临床领域中，通过程序性死亡受体1（PD-1）/程序性死亡受体配体1（PD-L1）阻断改善过继性T细胞免疫疗法的新见解不断涌现。
Mol Cancer. 2024 Apr 24;23(1):80. doi: 10.1186/s12943-023-01926-4.
2
Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study.接受免疫检查点抑制剂治疗的 EGFR 突变型非小细胞肺癌患者的临床特征：CS-Lung-003 前瞻性观察性注册研究。
J Cancer Res Clin Oncol. 2024 Feb 12;150(2):89. doi: 10.1007/s00432-024-05618-4.
3

本文引用的文献

1
A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.一项评估帕博利珠单抗在 EGFR 突变、PD-L1 阳性、初治的晚期 NSCLC 患者中的疗效和安全性的 II 期临床研究。
J Thorac Oncol. 2018 Aug;13(8):1138-1145. doi: 10.1016/j.jtho.2018.03.035. Epub 2018 Jun 1.
2
Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment.巨噬细胞阻碍 CD8 T 细胞到达肿瘤细胞，并限制抗 PD-1 治疗的效果。
Proc Natl Acad Sci U S A. 2018 Apr 24;115(17):E4041-E4050. doi: 10.1073/pnas.1720948115. Epub 2018 Apr 9.
3
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.
EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment.
表皮生长因子受体突变型非小细胞肺癌与免疫治疗抵抗：肿瘤微环境的作用。
Int J Mol Sci. 2022 Jun 10;23(12):6489. doi: 10.3390/ijms23126489.
4
Case Report: Opportunities and Challenges of Immunotherapy in Heavily-Treated EGFR-Mutant Advanced Squamous Cell Lung Carcinoma After Progression on EGFR-TKIs and Chemotherapy.病例报告：在表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）和化疗进展后，免疫疗法在经过大量治疗的EGFR突变型晚期肺鳞癌中的机遇与挑战
Front Oncol. 2022 Feb 28;12:820408. doi: 10.3389/fonc.2022.820408. eCollection 2022.
5
Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers.人类乳腺癌、结直肠癌、肺癌、卵巢癌和前列腺癌中的肿瘤相关巨噬细胞
Front Oncol. 2020 Oct 22;10:566511. doi: 10.3389/fonc.2020.566511. eCollection 2020.
6
Development and validation of the immune signature to predict distant metastasis in patients with nasopharyngeal carcinoma.免疫特征的建立与验证，以预测鼻咽癌患者的远处转移。
J Immunother Cancer. 2020 Apr;8(1). doi: 10.1136/jitc-2019-000205.
接受检查点抑制剂治疗的晚期非小细胞肺癌患者的生存相关临床和分子特征：系统评价和荟萃分析。
JAMA Oncol. 2018 Feb 1;4(2):210-216. doi: 10.1001/jamaoncol.2017.4427.
4
Nivolumab in non-small-cell lung cancer with EGFR mutation.纳武利尤单抗用于治疗表皮生长因子受体（EGFR）突变的非小细胞肺癌
Ann Oncol. 2018 Mar 1;29(3):777-778. doi: 10.1093/annonc/mdx745.
5
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.肿瘤相关巨噬细胞的PD-1表达抑制吞噬作用和肿瘤免疫。
Nature. 2017 May 25;545(7655):495-499. doi: 10.1038/nature22396. Epub 2017 May 17.
6
Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.治疗早期 PD-L1 表达和免疫浸润的动态变化可预测黑色素瘤对 PD-1 阻断的反应。
Clin Cancer Res. 2017 Sep 1;23(17):5024-5033. doi: 10.1158/1078-0432.CCR-16-0698. Epub 2017 May 16.
7
Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.基于 EGFR-TKI 治疗后疾病进展时 T790M 状态的肿瘤免疫微环境和纳武利尤单抗在 EGFR 突变阳性非小细胞肺癌中的疗效。
Ann Oncol. 2017 Jul 1;28(7):1532-1539. doi: 10.1093/annonc/mdx183.
8
Prior radiotherapy does not predict nivolumab response in non-small-cell lung cancer: a retrospective cohort study.
Ann Oncol. 2017 Jun 1;28(6):1402. doi: 10.1093/annonc/mdx114.
9
The Promise of Targeting Macrophages in Cancer Therapy.靶向治疗癌症中的巨噬细胞：前景可期。
Clin Cancer Res. 2017 Jul 1;23(13):3241-3250. doi: 10.1158/1078-0432.CCR-16-3122. Epub 2017 Mar 24.
10
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.《转移性 EGFR 突变非小细胞肺癌中免疫检查点抑制剂的Meta 分析》
J Thorac Oncol. 2017 Feb;12(2):403-407. doi: 10.1016/j.jtho.2016.10.007. Epub 2016 Oct 17.